LGL Group (NYSEAMERICAN:LGL) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?
by Scott Moore · The Cerbat GemLGL Group, Inc. (The) (NYSEAMERICAN:LGL – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.51 and traded as high as $7.21. LGL Group shares last traded at $7.21, with a volume of 2,522 shares trading hands.
LGL Group Price Performance
The stock has a market capitalization of $46.96 million, a price-to-earnings ratio of 65.27 and a beta of 0.34. The stock’s 50 day simple moving average is $7.14 and its 200-day simple moving average is $6.52.
LGL Group (NYSEAMERICAN:LGL – Get Free Report) last posted its earnings results on Monday, March 30th. The industrial products company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.09). The business had revenue of $0.80 million during the quarter, compared to analyst estimates of $9.10 million. LGL Group had a net margin of 16.50% and a return on equity of 1.62%. As a group, equities research analysts anticipate that LGL Group, Inc. will post 0.12 earnings per share for the current fiscal year.
Institutional Trading of LGL Group
A hedge fund recently raised its stake in LGL Group stock. Osaic Holdings Inc. boosted its position in LGL Group, Inc. (The) (NYSEAMERICAN:LGL – Free Report) by 15.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,250 shares of the industrial products company’s stock after buying an additional 2,710 shares during the quarter. Osaic Holdings Inc. owned approximately 0.38% of LGL Group worth $154,000 at the end of the most recent reporting period. 30.28% of the stock is currently owned by institutional investors.
LGL Group Company Profile
LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.
The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.